MRD negativity as a treatment endpoint in CLL

Measurable residual disease (MRD) negativity is an important treatment endpoint for many hematological malignancies and has the potential to be used to inform therapy cessation decision making. Here, ... Author: VJHemOnc Added: 08/07/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts